Skip to content

Postpartum Evaluation of Nifedipine and Enalapril for Hypertension

Postpartum Evaluation of Antihypertensives for Control of Hypertension: A Randomized Controlled Equivalence Study

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07023003
Acronym
PEACE
Enrollment
850
Registered
2025-06-15
Start date
2025-07-11
Completion date
2028-12-31
Last updated
2025-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension in Pregnancy

Keywords

Hypertension, Postpartum, Enalapril, Nifedipine, Readmission

Brief summary

This is an open label, randomized controlled trial designed to compare nifedipine and enalapril in the management of postpartum hypertension. This is an equivalence study- meaning it is not expected one medication is better than the other. Nifedipine has been shown to be better than another common blood pressure medicine, labetalol, for postpartum hypertension but enalapril which is also used worldwide to manage blood pressure postpartum, has not yet been evaluated or compared to nifedipine. Investigators will identify and offer enrollment to women who are admitted for delivery with documented hypertension- participants with either chronic hypertension or pregnancy related hypertension will be included. Our hypothesis is both medications are safe and effective in managing blood pressure and preventing readmission for hypertensive complications during the postpartum period so evaluating the rate of readmission is the primary goal of the study. The only intervention of the trial will be to assign which medication the participant starts taking. Any decisions after that point- stopping medication, changing doses, additional medications, discharge from the hospital, etc, will all be at the discretion of the participant's primary provider.

Interventions

DRUGEnalapril 10mg QD

Enalapril 10mg PO QD will be given to manage postpartum hypertension. Duration of treatment to be dictated by primary provider.

DRUGNifedipine 30mg XL BID

Nifedipine 30mg XL BID will be given to manage postpartum hypertension. Duration of treatment to be dictated by primary provider.

Sponsors

Methodist Hospital Foundation
CollaboratorUNKNOWN
Nebraska Methodist Health System
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Open Label Randomized Controlled Equivalence Study

Eligibility

Sex/Gender
FEMALE
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. admitted for delivery by cesarean or vaginal delivery 2. 24 weeks gestation or greater 3. Pregnancy related hypertension(HTN) or chronic hypertension. Pregnancy related hypertension will be defined during the study as either a systolic blood pressure ≥140mmHg or diastolic blood pressure ≥90mmHg on two occasions at least 4 hours apart. This definition is consistent with the ACOG definition for pregnancy related HTN in patients without CHTN.

Exclusion criteria

1. Absolute contraindication to either nifedipine or enalapril Relative contraindications will be reviewed with PI. 2. Persistent HR \<60 or \>110 3. Native language other than English

Design outcomes

Primary

MeasureTime frameDescription
Hospital ReadmissionWithin 6 weeks of deliveryNumber of participants meeting criteria for hospital admission.

Countries

United States

Contacts

Primary ContactTodd Lovgren, MD
todd.lovgren@nmhs.org14028151970
Backup ContactJoshua Dahlke, MD
joshua.dahlke@nmhs.org14028151970

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026